Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)
Retrieved on:
Friday, July 16, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Health sciences, Life sciences, Medicine, Orphan drugs, Medical tests, Biostatistics, Companion diagnostic, Medical diagnosis, Novartis, Capmatinib, Foundation Medicine, Medication, FoundationOne Liquid CDx, Foundation Medicine, FOUNDATIONONE LIQUID CDX, FOUNDATION MEDICINE
[2] Today's approval adds to the number of therapies for which both of Foundation Medicines FDA-approved comprehensive genomic tests are listed as companion diagnostics.
Key Points:
- [2] Today's approval adds to the number of therapies for which both of Foundation Medicines FDA-approved comprehensive genomic tests are listed as companion diagnostics.
- FoundationOneCDx, Foundation Medicines tissue test, was approved as a companion diagnostic for TABRECTA in May 2020.
- TABRECTA is the second therapy for which both of Foundation Medicines FDA-approved tests, FoundationOne CDx and FoundationOne Liquid CDx, are listed as companion diagnostics.
- Foundation Medicine and FoundationOne are registered trademarks of Foundation Medicine, Inc.
TABRECTA is a trademark of Novartis.